NCT00396084View on ClinicalTrials.gov

Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 10, 2004

Primary Completion Date

November 23, 2007

Study Completion Date

December 28, 2007

Conditions

Tuberculosis

Interventions

DRUG

Gatifloxacin

Gatifloxacin 400 mg/day x 7 days.

DRUG

Isoniazid

Isoniazid 300 mg/day x 7 days.

DRUG

Levofloxacin

Levofloxacin 1000 mg/day x 7 days.

DRUG

Linezolid

Linezolid 600 mg/day x 7 days; Linezolid 600 mg every 12 hours x 7 days.

DRUG

Moxifloxacin

Moxifloxacin 400 mg/day x 7 days.

Trial Locations (2)

94110-3518

San Francisco General Hospital - Pulmonary and Critical Care Medicine, San Francisco

29040-091

Universidade Federal do Espirito Santo - Duke Hubert-Yeargan Center, Vitória

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00396084 - Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis | Biotech Hunter | Biotech Hunter